RPF patients are found to be more prone to developing ED. Penile plaque formation was identified in RPF patients, which may be presumed to relate to the pathological changes of the RPF process, but it remains unclear that these patients demonstrate a higher incidence of plaque formation than the normal population.
This study aimed to address the prevalence, the risk factors and the results of fecal carriage of extended-spectrum betalactamase producing Enterobacteriaceae (ESBL-PE) in patients who had undergone transrectal needle biopsy of the prostate (TRNBP).Patients and Methods: A total of 143 patients who had undergone TRNBP were included. Of these, 33(23%) had fecal carriage of ESBL-PE. The mean age of the patients was 62 ± 7.5 (43-81) years.Results: A univariate analysis showed that quinolone or other antibiotic use within the last 2 months, prostatitis, and diabetes mellitus (DM) were significantly associated with the presence of ESBL-PE. A multivariate analysis showed that quinolone use within the past 2 months (OR: 4.865; CI: 1.45-16.1), and DM (OR: 4.04; CI: 1.64-10) were found to be significant. Development of dysuria (p<0.001), fever (p=0.046) and chills (p=0.002) after TRNBP were shown to be related to the presence of ESBL-PE . There was no asymptomatic bacteriuria and sepsis, the rate of symptomatic urinary tract infection was 19%.Conclusion: This study showed that pre-biopsy risk factors for the presence of ESBL-PE were quinolone or other antibiotic use within the last 2 months and presence of DM. Changing prophylactic regimens should not be recommended due to the low rate of severe complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.